Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EVAGELOS COSKINAS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1437382314
CMS profile
201763
Location
RIVERSIDE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$92.48

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $92.48 5

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Sunovion Pharmaceuticals Inc. $44.65 3
Alkermes, Inc. $24.44 1
Janssen Pharmaceuticals, Inc $23.39 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EVAGELOS COSKINAS

NPI 1437382314 · CMS profile ID 201763

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

RIVERSIDE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437382314?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437382314?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437382314?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1437382314?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $92.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sunovion Pharmaceuticals Inc. $11.7509/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688090291 CMS
Sunovion Pharmaceuticals Inc. $16.1906/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688090289 CMS
Janssen Pharmaceuticals, Inc $23.3903/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658463767 CMS
Sunovion Pharmaceuticals Inc. $16.7102/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688090287 CMS
Alkermes, Inc. $24.4402/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686582037 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $92.48 5
PY2020 $28.27 1
PY2021 $85.12 1
PY2022 $87.50 1
PY2023 $75.07 3
PY2024 $497.65 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,435,713.44 192
PY2024 Principal investigator $1,112,891.48 274
PY2023 Principal investigator $145,338.68 81
PY2021 Principal investigator $14,588.05 4
PY2020 Principal investigator $129,452.46 74
PY2019 Principal investigator $432,130.59 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $6,235.20 12/16/2019 Non-covered Recipient Entity
CITRIALS INC
A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE No dispute reported 06/30/2026 753394289
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,946.70 12/05/2019 Non-covered Recipient Entity
CITRIALS INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685012831
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 12/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577815
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $602.10 11/28/2019 Non-covered Recipient Entity
CITRIALS INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685012817
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,367.90 11/13/2019 Non-covered Recipient Entity
CITRIALS INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685012809
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 11/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577559
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,408.40 10/16/2019 Non-covered Recipient Entity
CITRIALS INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685012795
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 10/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577623
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $602.10 09/25/2019 Non-covered Recipient Entity
CITRIALS INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685010459
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,034.80 09/25/2019 Non-covered Recipient Entity
CITRIALS INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685010469
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $301.05 09/04/2019 Non-covered Recipient Entity
CITRIALS INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685010453
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 09/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577479
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,668.95 08/07/2019 Non-covered Recipient Entity
CITRIALS INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685010443
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 08/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577415
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,592.70 07/17/2019 Non-covered Recipient Entity
CITRIALS INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685010435
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $3,624.52 07/10/2019 Non-covered Recipient Entity
CITRIALS INC
A MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH BIPOLAR I DISORDER No dispute reported 06/30/2026 696054719
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 07/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577153
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $301.05 06/12/2019 Non-covered Recipient Entity
CITRIALS INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685007589
Principal investigator 1 Genentech, Inc. $273.00 06/05/2019 Non-covered Recipient Entity
CITRIALS INC
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 681082353
Principal investigator 1 Genentech, Inc. $5,187.00 06/05/2019 Non-covered Recipient Entity
CITRIALS INC
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 681092687
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 06/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576757
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,360.55 05/29/2019 Non-covered Recipient Entity
CITRIALS INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685007585
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $840.20 05/28/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576739
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 05/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576661
Principal investigator 1 Merck Sharp & Dohme Corporation $5,000.00 04/09/2019 Non-covered Recipient Entity
CITRIALS
A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of suvorexant MK-4305 for the Treatment of Sleep Disturbance in Patients with Alzheimer s Disease No dispute reported 06/30/2026 691313339
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 04/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576567
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $1,151.14 03/26/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576185
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,000.00 03/07/2019 Non-covered Recipient Entity
CITRIALS INC
ACP-103-034 No dispute reported 06/30/2026 699988653
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 03/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576405
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $116.42 02/25/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576183
Principal investigator 1 Merck Sharp & Dohme Corporation $8,577.50 02/12/2019 Non-covered Recipient Entity
CITRIALS
A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of suvorexant MK-4305 for the Treatment of Sleep Disturbance in Patients with Alzheimer s Disease No dispute reported 06/30/2026 691313221
Principal investigator 1 Merck Sharp & Dohme Corporation $16,338.75 02/12/2019 Non-covered Recipient Entity
CITRIALS
A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of suvorexant MK-4305 for the Treatment of Sleep Disturbance in Patients with Alzheimer s Disease No dispute reported 06/30/2026 691314009
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 02/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576295
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $40.00 02/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576355
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $12.50 02/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576357
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $664.10 01/28/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576181
Principal investigator 1 ACADIA Pharmaceuticals Inc $4,987.00 01/25/2019 Non-covered Recipient Entity
CITRIALS INC
ACP-103-034 No dispute reported 06/30/2026 699988269
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $168,875.51 01/10/2019 Non-covered Recipient Entity
CITRIALS INC
PROTOCOL 331-201-00081 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE ACUTE TREATMENT OF MANIC EPISODES, WITH OR WITHOUT MIXED FEATURES, ASSOCIATED WITH BIPOLAR I DISORDER No dispute reported 06/30/2026 696052912
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $177,609.85 01/03/2019 Non-covered Recipient Entity
CITrials Inc
PoCC dose finding in Mild to Moderate AD No dispute reported 06/30/2026 704143337
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 01/01/2019 Non-covered Recipient Entity
CITRIALS
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576021